H
Harold J. Burstein
Researcher at Harvard University
Publications - 342
Citations - 35924
Harold J. Burstein is an academic researcher from Harvard University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 82, co-authored 306 publications receiving 30671 citations. Previous affiliations of Harold J. Burstein include American Society of Clinical Oncology & Alliance for Clinical Trials in Oncology.
Papers
More filters
Journal ArticleDOI
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch,E P Winer,A S Coates,R. D. Gelber,M Piccart-Gebhart,B. Thürlimann,H.-J. Senn,Kathy S. Albain,Fabrice Andre,Jonas Bergh,Hervé Bonnefoi,Denisse Bretel-Morales,Harold J. Burstein,Fatima Cardoso,M. Castiglione-Gertsch,Alan S. Coates,Marco Colleoni,Alberto Costa,Giuseppe Curigliano,Nancy E. Davidson,Angelo Di Leo,Bent Ejlertsen,John F. Forbes,Richard D. Gelber,Michael Gnant,Aron Goldhirsch,Pamela J. Goodwin,Paul E. Goss,Jay R. Harris,Daniel F. Hayes,Clifford A. Hudis,James N. Ingle,Jacek Jassem,Zefei Jiang,Per Karlsson,Sibylle Loibl,Monica Morrow,Moïse Namer,C. Kent Osborne,Ann H. Partridge,Frédérique Penault-Llorca,Charles M. Perou,Martine Piccart-Gebhart,Kathleen I. Pritchard,Emiel J. Th. Rutgers,Felix Sedlmayer,Vladimir Semiglazov,Z Shao,Ian E. Smith,Beat Thürlimann,Masakazu Toi,Andrew Tutt,Michael Untch,Giuseppe Viale,Toru Watanabe,Nicholas Wilcken,Eric P. Winer,William C. Wood +57 more
TL;DR: The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy.
Journal ArticleDOI
American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
Gary H. Lyman,Armando E. Giuliano,Mark R. Somerfield,Al B. Benson,Diane C. Bodurka,Harold J. Burstein,Alistair J. Cochran,Hiram S. Cody,Stephen B. Edge,Sharon Galper,James A. Hayman,Theodore Y. Kim,Cheryl L. Perkins,Donald A. Podoloff,Visa Haran Sivasubramaniam,Roderick R. Turner,Richard L. Wahl,Donald L. Weaver,Antonio C. Wolff,Eric P. Winer +19 more
TL;DR: A review of the available evidence demonstrates that, when performed by experienced clinicians, SNB appears to be a safe and acceptably accurate method for identifying early-stage breast cancer without involvement of the axillary lymph nodes.
Journal ArticleDOI
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
Eric P. Winer,Clifford A. Hudis,Harold J. Burstein,Antonio C. Wolff,Kathleen I. Pritchard,James N. Ingle,Rowan T. Chlebowski,Richard D. Gelber,Stephan B. Edge,Julie Gralow,Melody A. Cobleigh,Eleftherios P. Mamounas,Lori J. Goldstein,Timothy J. Whelan,Trevor J. Powles,John Bryant,Cheryl L. Perkins,Judy Perotti,Susan Braun,Amy S. Langer,George P. Browman,Mark R. Somerfield +21 more
TL;DR: It is believed that optimal adjuvant hormonal therapy for a postmenopausal woman with receptor-positive breast cancer includes an aromatase inhibitor as initial therapy or after treatment with tamoxifen.
Journal ArticleDOI
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar,Benjamin O. Anderson,Jame Abraham,Rebecca Aft,Doreen M. Agnese,Kimberly H. Allison,Sarah L. Blair,Harold J. Burstein,Chau T. Dang,Anthony D. Elias,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Jairam Krishnamurthy,Janice A. Lyons,P. Kelly Marcom,Jennifer M. Matro,Ingrid A. Mayer,Meena S. Moran,Joanne E. Mortimer,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Hope S. Rugo,Amy M. Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,Erica Stringer-Reasor,Melinda L. Telli,John H. Ward,Jessica Young,Jennifer L. Burns,Rashmi Kumar +34 more
TL;DR: The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
Journal ArticleDOI
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell,Harold J. Burstein,Anna Maria Storniolo,Hope S. Rugo,George W. Sledge,Maria Koehler,Catherine E. Ellis,Michelle Casey,Svetislava J. Vukelja,Joachim Bischoff,José Baselga,Joyce O'Shaughnessy +11 more
TL;DR: Despite disease progression on prior trastuzumab-based therapy, lapatinib in combination with trastzumab significantly improved PFS and CBR versus lapatinIB alone, thus offering a chemotherapy-free option with an acceptable safety profile to patients with ErbB2-positive MBC.